Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.32
    OpenPayerPolicy UpdatesClinical/Medical PolicyOscar Health vaginitis testing Coverage Update | O…
    Ask Trek AI about this page

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    CurrentOscar HealthPolicy N/A

    Diagnosis of Vaginitis

    Customize your policy alerts

    Sign up for all Oscar Health policy alerts

    Know when Oscar Health releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Criteria and coverage guidance for laboratory and office diagnostic testing used to evaluate vaginitis (BV, vulvovaginal candidiasis, and trichomoniasis) in individuals with signs and symptoms; intended for providers submitting claims to Oscar Health.

    Policy Summary
    PayerOscar Health
    PolicyDiagnosis of Vaginitis
    Policy CodePolicy N/A
    Change TypeNo material clinical or coverage changes
    Effective DateOct 1, 2026
    Last ReviewJun 16, 2026
    Next Review DateJun 16, 2026
    Key ActionDocument clinical history, exam findings, and appropriate laboratory testing when ordering vaginitis diagnostic tests to support medical necessity and claims submission.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    7numbered coverage rules for symptomatic individuals
    95%Aptima BV sensitivity
    5FDA-cleared multiplex assays named
    $2,067healthcare cost savings with syndromic PCR
    3 monthsretest interval after trichomoniasis

    Coverage Criteria for Vaginitis Testing

    Covered Testing for Symptomatic Individuals

    Covered when ALL of the following are met for individuals with signs and symptoms of vaginitis:

    Basic office/point-of-care testing: Testing of pH, amine (whiff) test, measurement of sialidase activity, saline wet mount, potassium hydroxide (KOH) wet mount, and microscopic examination of vaginal fluids

    Meets criteria for symptomatic individuals

    Direct-probe DNA multi-pathogen panel: Multi-pathogen panel test using direct-probe DNA-based identification of Gardnerella, Trichomonas, and Candida (e.g., BD Affirm VPIII)

    Meets criteria for symptomatic individuals

    Vaginal culture for Candida after negative wet mount/normal pH: Vaginal cultures for Candida species when wet-mount preparations are negative and pH is normal

    Meets criteria

    Policy Summary
    PayerOscar Health
    PolicyDiagnosis of Vaginitis
    Policy CodePolicy N/A
    Change TypeNo material clinical or coverage changes
    Effective DateOct 1, 2026
    Last ReviewJun 16, 2026
    Next Review DateJun 16, 2026
    Key ActionDocument clinical history, exam findings, and appropriate laboratory testing when ordering vaginitis diagnostic tests to support medical necessity and claims submission.
    SourceLink
    On This Page
    Coverage Criteria for Vaginitis TestingAssays, Tests, and Procedure CodesProvider Actions, Documentation, and Prior AuthorizationBackground and ScopeDefinitions and Abbreviations
    NAAT for complicated VVC: NAAT-based identification of Candida to confirm clinical diagnosis and identify non-albicans species in complicated vulvovaginal candidiasis

    Meets criteria

    NAAT specific for BV: NAAT tests specific to the diagnosis of BV (e.g., Aptima BV; OneSwab BV Panel with Lactobacillus profiling; SureSwab Advanced BV, TMA) and single or multitarget PCR

    Meets criteria

    NAAT panel for multiple vaginitis types: NAAT panel testing designed to detect more than one type of vaginitis (VVC, BV, and/or trichomoniasis; e.g., BD MAX Vaginal Panel, NuSwab VG, Xpert Xpress MVP) with frequency limit of no more than one test every seven daysno more than once per 7 days

    Meets criteria

    Not Medically Necessary / Not Covered Testing

    Not covered or not meeting criteria:

    Asymptomatic screening: Screening asymptomatic individuals (including asymptomatic pregnant individuals at average or high risk for preterm labor) for trichomoniasis and bacterial vaginosis

    Does not meet criteria

    Other NAT/NAAT for Candida or Gardnerella: Nucleic acid testing (NAT) for Candida (quantitative NAAT, direct probe testing) or Gardnerella not described in covered criteria

    Does not meet criteria

    Testing for vaginal flora/infertility panels: Testing for microorganisms involved in vaginal flora imbalance and/or infertility using molecular-based panel testing

    Does not meet criteria due to lack of supportive literature

    Broad combined vaginitis/STI panels not addressed: Broad molecular panels designed to concurrently test for vaginitis and various other STIs not specifically addressed in covered items

    Does not meet criteria

    When diagnostic testing is appropriate

    Covered when clinical evaluation or circumstances warrant laboratory confirmation:

    Symptomatic patients: Symptomatic individuals with vaginal symptoms (e.g., itching, burning, odor, abnormal discharge) undergoing evaluation

    Many studies and assays evaluated symptomatic populations

    Diagnostic methods appropriate: At least one of: office-based tests (pH, KOH, microscopy) OR commercial molecular/point-of-care tests (NAAT, TMA, qPCR, chromogenic assays) when microscopy unavailable or to increase diagnostic accuracy

    CDC and guideline bodies endorse office tests; molecular tests acceptable when office testing unavailable or to improve accuracy

    Test selection considerations: Selection of molecular testing may be preferred when higher sensitivity/specificity or single-visit diagnosis is desired

    Evidence shows molecular assays have higher sensitivity/specificity and potential cost-savings versus no diagnostic testing

    Diagnostic testing — symptomatic patients

    Covered when ALL of the following are met

    Symptomatic testing indication: Patient is symptomatic (vaginal discharge, odor, itch, or other vaginal symptoms)

    Multiplex NAATs and other assays are intended for symptomatic women only

    Specimen and test selection: Testing is ordered using an appropriate specimen type (clinician- or self-collected vaginal swab) and an assay intended/cleared for use in the patient's age group

    FDA-cleared assays specify specimen and age indications; choose assay consistent with intended use

    Use of standard office diagnostics: When available, initial office-based tests (pH, KOH whiff test, wet mount microscopy) are used; multiplex NAATs are an alternative with higher sensitivity but higher cost

    CDC and professional guidelines endorse office diagnostics as initial approach; NAATs offer greater sensitivity for symptomatic patients

    Asymptomatic screening — discouraged

    Not routinely covered/indicated when ANY of the following apply

    Asymptomatic screening in pregnancy: Asymptomatic pregnant persons not at increased risk for preterm delivery should not be routinely screened for bacterial vaginosis

    USPSTF and CDC recommend against routine screening in low-risk asymptomatic pregnant persons

    Asymptomatic patients: Multiplex NAATs and BV NAATs are not intended for screening asymptomatic patients and should not be used for prognostic purposes or test-of-cure

    Guidelines state these assays are for symptomatic women only

    Follow-up testing

    Follow-up testing recommended when ANY of the following are met

    Persistent or recurrent symptoms: Patient has persistent or recurrent symptoms after treatment for BV, VVC, or trichomoniasis; retesting and clinical evaluation are recommended

    CDC and AAFP recommend return for evaluation when symptoms persist or recur

    Trichomoniasis retesting interval: Sexually active women treated for trichomoniasis should be retested approximately 3 months after initial treatment~3 months

    CDC, ACOG, and AAFP recommend retesting due to high reinfection rates

    Molecular-based panel testing that targets microorganisms involved in vaginal flora imbalance or infertility does not meet criteria when there is insufficient published evidence demonstrating clinical benefit. Examples include large molecular panels and broad combined vaginitis/STI panels that are not specifically addressed in covered items; these tests are not supported for routine use in the diagnosis or management of vaginitis in the absence of validated clinical utility.

    Vaginal culture is not recommended for the diagnosis of bacterial vaginosis because BV represents complex changes in vaginal flora that are not defined by culture. Diagnosis of BV is based on clinical criteria (e.g., Amsel) or Gram-stain scoring (Nugent); when microscopy is unavailable, validated commercial tests may be used instead.

    Cervical Pap tests and culture for Gardnerella vaginalis have no clinical utility for diagnosing bacterial vaginosis due to low sensitivity and specificity. In addition, multiplex NAATs and other multiplex vaginal panels are intended for symptomatic women only and are not recommended for asymptomatic screening, prognostic use, or as tests-of-cure.

    Laboratory-developed tests (LDTs) discussed in this policy are not FDA-approved; they are regulated by CMS under CLIA as high-complexity tests. LDTs require in‑house validation and CLIA compliance prior to clinical use.

    Within the provided source excerpts there are no explicit coverage exclusions beyond the specific limitations and not‑meeting‑criteria statements cited elsewhere; the remaining content in these chunks consists of bibliographic references and guideline citations.

    Broad molecular panels designed to concurrently test for vaginitis and other sexually transmitted infections are not addressed as covered in the policy statements and, where not specifically included among covered items, are considered not indicated due to lack of demonstrated benefit in the literature.

    Molecular assays and multiplex NAATs can improve diagnostic accuracy but are generally more costly than traditional methods. The document notes that these assays are expensive and that broader-target molecular panels increase costs without proven incremental clinical benefit for some indications (for example, when microscopy or targeted culture would suffice). Cost considerations should be weighed against potential clinical advantages on a case-by-case basis.

    Routine screening for bacterial vaginosis in asymptomatic pregnant persons who are not at increased risk for preterm delivery is not recommended, consistent with USPSTF and CDC guidance; screening in low‑risk pregnant individuals does not prevent preterm birth and therefore should be avoided.

    In the provided excerpts there are no explicit statements framed solely as a blanket 'not medically necessary' designation beyond the specific not‑meeting‑criteria and exclusion items already cited; most guidance is presented as coverage limitations tied to clinical indications or lack of supporting literature.

    Assays, Tests, and Procedure Codes

    Examples of referenced proprietary/assay tests (not billing codes)mixed
    No codes listed
    Referenced diagnostic assaysmixed
    OneSwab® (MDL)qPCR/real-time PCR panel with BV (Lactobacillus profiling) detecting Gardnerella, Atopobium, Megasphaera, BVAB2
    SureSwab® Advanced BV (Quest) TMATMA-based assay screening BV organisms; reports qualitative BV result
    Aptima® CV/TVNAAT assays detecting BV, vulvovaginal candidiasis (Candida spp.), and Trichomonas vaginalis from one vaginal sample
    BD MAX™ Vaginal PanelReal-time PCR panel detecting BV-associated bacteria, Candida species, and Trichomonas vaginalis
    OSOM® BVBlue®Chromogenic point-of-care test detecting elevated sialidase activity associated with BV
    Named multiplex vaginal NAAT assays and panelsmixed
    BD Max Vaginal PanelFDA-cleared multiplex PCR panel detecting BV targets plus Candida species and T. vaginalis
    Aptima BVFDA-approved NAAT (TMA) for detection/identification of bacterial vaginosis; qualitative BV result on Panther system
    NuSwab VG / OneSwab BV Panel / SureSwab BVLaboratory-developed or commercial multiplex PCR/TMA assays for BV (varies by lab; some LDTs)
    Xpert Xpress Multiplex vaginal panel (MVP)FDA-cleared multiplex vaginal panel (Cepheid)
    Applicable CPT/HCPCS Procedure Codesmixed
    81513Infectious disease, bacterial vaginosis, quantitative real-time amplification of RNA markers for Atopobium vaginae, Gardnerella vaginalis, and Lactobacillus species; vaginal-fluid specimens; algorithm reported as a positive or negative result for bacterial vaginosis.
    81514Infectious disease, bacterial vaginosis and vaginitis, quantitative real-time amplification of DNA markers for Gardnerella vaginalis, Atopobium vaginae, Megasphaera type 1, BVAB-2, and Lactobacillus species; includes separate detection of Trichomonas and/or Candida species when reported.
    0505UInfectious disease (vaginal infection), identification of 32 pathogenic organisms, real-time PCR, reported as positive or negative for each organism.
    82120Amines, vaginal fluid, qualitative.
    83986pH; body fluid, not otherwise specified.
    87070Culture, bacterial; any other source except urine, blood or stool, aerobic, with isolation and presumptive identification of isolates.
    87149Culture, typing; identification by nucleic acid (DNA or RNA) probe, direct probe technique, per culture or isolate, each organism probed.
    87150Culture, typing; identification by nucleic acid (DNA or RNA) probe, amplified probe technique, per culture or isolate, each organism probed.
    87210Smear, primary source with interpretation; wet mount for infectious agents (e.g., saline, India ink, KOH preps).
    87480Infectious agent detection by nucleic acid (DNA or RNA); Candida species, direct probe technique.
    1–10 of 21
    1/3
    Vaginal pH — BV threshold (premenopausal)
    Vaginal pH threshold (premenopausal)> 4.5
    Normal premenopausal vaginal pH range4.0 to 4.5
    Normal low-estrogen (prepubertal/postmenopausal) pH>= 4.7
    Factors that may alter pHLubricants, semen, douches, intravaginal meds, amniotic fluid leakage
    Vaginal pH — Trichomoniasis
    Vaginal pH suggestive of trichomoniasis5 to 6
    pH role in differential diagnosisElevated pH helps distinguish trichomoniasis from Candida
    Potential pH confoundersLubricants, semen, douches, intravaginal meds
    Vaginal pH — Candida (VVC)
    Vaginal pH consistent with Candida (VVC)4 to 4.5
    Use of pH to exclude CandidaNormal/low pH makes Candida more likely compared with BV or TV
    Normal premenopausal pH range4.0 to 4.5
    Amsel positive criteria (3-of-4 rule)
    Amsel criteria definitionDiagnosis of BV when at least 3 of 4 findings are present: homogeneous thin discharge; vaginal pH > 4.5; positive amine (whiff) test with KOH; presence of clue cells on microscopy
    Use for presumptive treatmentIf 3 or 4 criteria present, presumptive treatment can be offered (per guidelines)
    Relation to microscopyAmsel criteria are clinic-based and commonly used alongside Gram stain/Nugent scoring

    Provider Actions, Documentation, and Prior Authorization

    Prior Authorization

    Authorization & medical necessity required

    Coverage and reimbursement for vaginitis diagnostic testing are subject to authorization and medical necessity; services must meet the member's benefit coverage at the time of request and follow applicable payer rules. Providers must confirm benefits and obtain any required authorizations prior to ordering tests.

    Note

    Use molecular and POC tests when clinically indicated

    Molecular (NAAT/TMA/qPCR) and point-of-care tests are described as clinically useful and may reduce downstream utilization and costs; order these tests when clinical evaluation indicates their use and in accordance with intended use described by the assay.

    • Syndromic PCR testing associated with reduced follow-up visits and cost savings in population data.
    Prior Authorization

    Order FDA-cleared multiplex NAATs for symptomatic patients only

    Some multiplex NAATs (e.g., BD MAX Vaginal Panel, Aptima assays, Xpert Xpress MVP) are FDA-cleared/approved for symptomatic women; order these assays consistent with their intended use (symptomatic patients) and platform labeling.

    • Multiplex NAATs are intended for symptomatic women and not for asymptomatic screening or test-of-cure.
    Note

    Codes provided for reference — no explicit prior auth stated here

    The policy provides CPT/HCPCS procedure codes for reference but does not state an explicit prior authorization requirement for the listed codes in this excerpt; use the codes for billing alignment and verify plan-specific prior authorization rules.

    • Example codes listed for reference include 81513, 81514, 0505U, 87800–87801, 87480–87482.
    Prior Authorization

    Prior authorization not specified in policy excerpts

    No specific payer-level prior authorization requirements are specified in these policy excerpts; providers must rely on local plan rules and benefit checks to determine if authorization is required.

    Step Therapy

    Minimum 7‑day retesting interval for multi-organism NAAT panels

    NAAT panels that detect BV, VVC, and TV should not be repeated before a seven-day minimum treatment window has passed for organisms treated with up to seven-day regimens; if symptoms persist despite treatment, individual organism testing may be performed within this window.

    • Do not repeat a multi-organism NAAT panel for all three vaginitis types sooner than 7 days after treatment initiation.
    Note

    Use office tests first; use commercial labs if unavailable

    Initial diagnostic evaluation should include office-based tests when available (vaginal pH, KOH whiff test, and wet mount microscopy); if these are unavailable, order appropriate commercial laboratory molecular or point-of-care tests.

    • Office diagnostics (pH, KOH, microscopy) are acceptable first-line tests per CDC and ACOG guidance.
    • Use commercial NAAT/TMA/qPCR assays when office testing is not available or to increase diagnostic accuracy.
    Step Therapy

    Follow-up testing and retreatment — retest per clinical guidance

    Follow-up testing and retreatment should be based on clinical circumstances: patients with persistent or recurrent symptoms should return for evaluation; for trichomoniasis, retesting is recommended approximately 3 months after treatment to detect reinfection.

    • Retest sexually active women treated for trichomoniasis about 3 months after initial treatment per CDC/ACOG.
    • Verify clinical status before retreatment or repeat testing.
    Note

    Reference placeholder (no new action stated)

    This chunk is a placeholder in the inventory; no additional explicit provider action is stated in the provided excerpt.

    Step Therapy

    No step therapy requirements specified

    No step therapy requirements are described in the provided text; providers should follow clinical guidance and payer-specific rules where applicable.

    Documentation Required

    Submit accurate documentation and use proper coding

    Providers must submit accurate documentation of services rendered and use appropriate industry-standard coding; failure to follow coding/billing guidelines or current reimbursement policies may result in claim denial or recoupment.

    • Code claims per CPT, HCPCS, ICD-10, and CMS/NCCI guidance.
    • Ensure documentation supports billed services.
    Documentation Required

    Document history, exam, and specific lab testing

    Document medical history, physical examination findings, and laboratory testing performed (vaginal pH, KOH whiff test, microscopy, or appropriate commercial molecular/POC tests) to support the clinical indication for testing.

    • Record symptoms, sexual history, vaginal exam findings, and which diagnostic tests were performed.
    • Note specimen type (clinician- or patient-collected vaginal swab) when using molecular assays.
    Documentation Required

    LDTs must be validated and CLIA-compliant

    Laboratory-developed tests (LDTs) are regulated under CLIA as high-complexity tests and must be validated by the performing laboratory; documentation of LDT validation and CLIA compliance may be required for their use.

    • LDTs are not FDA-approved and require in‑house validation under CLIA '88.
    Documentation Required

    Document specimen type and assay used (LDT or FDA-cleared)

    When using specific LDTs or FDA‑cleared assays (e.g., Aptima BV, BD MAX Vaginal Panel), document the specimen type, that the clinical presentation is consistent with vaginitis, and any validation or platform details needed to support use.

    • Specify clinician‑ or patient‑collected vaginal swab in documentation.
    • Reference the specific assay (Aptima BV, BD MAX) used when reporting results.
    Documentation Required

    No further documentation requirements specified here

    No additional documentation requirements are specified in these excerpts beyond those already stated; bibliographic references are listed in the evidence section.

    Denial Risk

    Risk of denial for incorrect coding or unsupported billing

    Claims may be denied or recouped if coding/billing guidelines, reimbursement policies, or documentation requirements are not followed; misuse of procedure codes provided for reference may also trigger denials.

    • Procedure codes in the policy are for reference and may not be all‑inclusive; verify correct coding before billing.
    Documentation Required

    Document clinical evaluation to support testing

    Failure to document a complete history, exam, and appropriate laboratory testing to determine the etiology of vaginal symptoms may lead to inappropriate management and potential claim denials; document findings to support the diagnostic choice.

    • Document clinical signs, pH, microscopy results, and rationale for molecular testing if ordered.
    Denial Risk

    Follow applicable government coverage policies when conflicts exist

    When there is a conflict between this policy and applicable government policies (e.g., Medicare LCDs/NCDs or state Medicaid rules), determinations must follow the relevant government policy.

    Billing Rule

    Procedure codes are reference only — verify before billing

    Procedure codes listed in this Medical Policy are provided only as a general reference and may not be all‑inclusive; improper use of the listed codes or billing without supporting documentation could result in claim denials.

    Prior Authorization

    No explicit authorization or denial criteria present in these excerpts

    These policy excerpts do not include explicit authorization or denial criteria; the section largely contains evidence references and guidance — verify plan-specific requirements and check benefits prior to ordering.

    Background and Scope

    Vaginitis is inflammation of the vagina that commonly causes discharge, itching, and discomfort. The most frequent etiologies are bacterial vaginosis (BV), vulvovaginal candidiasis (VVC), and trichomoniasis. Diagnosis relies on clinical assessment and office tests (vaginal pH, KOH whiff, microscopy/Amsel criteria, Nugent Gram stain), with molecular NAATs available to increase sensitivity and to identify specific pathogens when indicated.

    Definitions and Abbreviations

    NAAT — definition
    NAAT abbreviationNucleic acid amplification testing
    Common NAAT modalitiesIncludes PCR, real-time PCR, and TMA (transcription-mediated amplification)
    Specimen typesClinician- or self-collected vaginal swab specimens commonly used
    VVC — definition
    VVC abbreviationVulvovaginal candidiasis
    Clinical featuresTypically presents with normal/low vaginal pH (4.0–4.5) and visualization of yeast on microscopy
    Diagnostic confirmationWet-mount visualization or culture/commercial test may be used per ACOG guidance
    Amsel criteria — definition
    Amsel criteria — diagnostic definitionBacterial vaginosis is diagnosed when >= 3 of 4 findings are present: homogeneous thin discharge; vaginal pH > 4.5; positive whiff (KOH) test; clue cells on microscopy
    Sensitivity/specificity contextWhen compared with Gram stain, Amsel sensitivity >90% and specificity ~77% in some studies
    Clinical utilityCommonly used in clinic settings; supports presumptive treatment when criteria met
    Nugent score — definition
    Nugent score definitionGram stain–based scoring system for BV based on bacterial morphotypes from a vaginal swab
    Use caseUsed as reference standard in many studies and in specialized services
    Relation to AmselNugent scoring is an alternative/complement to Amsel clinical criteria
    Amsel's criteria — clinic-based definition
    Amsel's criteria (clinic-based)Clinical diagnostic criteria for BV requiring 3 of 4 findings (homogeneous discharge, pH>4.5, positive whiff test, clue cells)
    Guideline endorsementRecommended by Australian STI guidelines and referenced by ACOG/CDC for clinical diagnosis
    Role vs Gram stainUsed for presumptive treatment in primary care when microscopy is available
    Multiplex NAAT — definition
    Multiplex NAAT definitionMolecular assays that detect multiple targets (e.g., BV-associated bacteria, Candida spp., Trichomonas vaginalis) from a single vaginal specimen
    Intended useDesigned for symptomatic women and not for asymptomatic screening or test-of-cure
    ExamplesBD MAX Vaginal Panel, Aptima BV, NuSwab VG, OneSwab BV Panel, SureSwab BV
    Laboratory-developed test (LDT) — definition & regulatory status
    Laboratory-developed test (LDT)A test developed and validated in-house by a laboratory; regulated by CMS under CLIA as high-complexity tests and not FDA-approved
    Regulatory noteLDTs are not FDA-approved/cleared but are permitted for clinical use under CLIA regulation
    Validation requirementLabs must validate performance characteristics prior to clinical use
    Aptima BV Assay — definition
    Aptima BV Assay — definitionAn in vitro nucleic acid amplification (TMA) assay that detects and quantifies ribosomal RNA from bacteria associated with BV and reports a qualitative BV result for clinician- or patient-collected vaginal swabs
    Regulatory statusFDA-approved for aiding BV diagnosis on the Hologic Panther system
    Targets detectedIncludes Lactobacillus spp., Gardnerella vaginalis, and Atopobium vaginae among assessed organisms
    Evidence and guideline sources cited
    Evidence sources — guideline listUSPSTF, ACOG Practice Bulletin 215, IDSA/ASM guidance, CDC STIs Treatment Guidelines
    Additional referencesAAFP reviews and international guidelines (Australian STI Management), ECMM/ISHAM candidiasis guidance
    Bibliography sizeDocument cites ~30+ references supporting diagnostic and coverage statements